Fulcrum Therapeutics, Inc. (FULC) NASDAQ

7.29

-0.375(-4.90%)

Updated at September 08 03:03PM

Currency In USD

Fulcrum Therapeutics, Inc.

Address

26 Landsdowne Street

Cambridge, MA 02139

United States of America

Phone

617 651 8851

Sector

Healthcare

Industry

Biotechnology

Employees

45

First IPO Date

July 18, 2019

Key Executives

NameTitlePayYear Born
Mr. Alexander C. SapirChief Executive Officer, President & Director1M1967
Mr. Curtis G. Oltmans J.D.Senior Vice President, Chief Legal Officer & Corporate Secretary572,1001963
Dr. Rudolf Jaenisch M.D., Ph.D.Founder0N/A
Dr. Jeffrey W. Jacobs Ph.D.Chief Scientific Officer01963
Ms. Kim HazenChief People Officer0N/A
Mr. Gregory TourangeauController & Principal Accounting Officer0N/A
Dr. Bradley E. Bernstein M.D., Ph.D.Founder0N/A
Dr. Danny ReinbergFounder0N/A
Dr. Michael R. GreenFounder0N/A
Dr. Tsun-Huei Lee M.D., Ph.D.Founder01964

Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.